A Seattle venture firm focusing its investments on biopharmaceutical companies is raising a new $400 million fund, according to U.S. Securities and Exchange Commission filings made last week.
Frazier Healthcare’s seventh fund follows a $600 million fund formed in 2008.
The firm’s investment strategy focuses on companies with development-stage biopharmaceutical therapeutics and occasionally medical devices.
To read the full, original article click on this link: Biopharmaceutical VC firm Frazier Healthcare raising new $400 million fund
